High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes

British Journal of Haematology

Volumn 167, Issue 1, 2014, Pages 100-109

  Alhan, Canan ^a   Westers, Theresia M ^a   Cremers, Eline M P ^a   Cali, Claudia ^a   Witte, Birgit I ^a   Ossenkoppele, Gert J ^a   van de Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Flow cytometry; IPSS R; Myelodysplastic syndromes; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FLOW CYTOMETRIC SCORING SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM; SCORING SYSTEM; VERY ELDERLY; BONE MARROW; BONE MARROW CELL; CASE CONTROL STUDY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

BIOLOGICAL MARKER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW CELLS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909981806     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12994     Document Type: Article

References (26)

1. Bejar, R., Stevenson, K.E., Caughey, B.A., Abdel-Wahab, O., Steensma, D.P., Galili, N., Raza, A., Kantarjian, H., Levine, R.L., Neuberg, D., Garcia-Manero, G. & Ebert, B.L. (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology, 30, 3376-3382.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
3. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Löwenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
4. Chu, S.C., Wang, T.F., Li, C.C., Kao, R.H., Li, D.K., Su, Y.C., Wells, D.A. & Loken, M.R. (2011) Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leukemia Research, 35, 868-873.
5. Cutler, J.A., Wells, D.A., van de Loosdrecht, A.A., de Baca, M.E., Kalnoski, M.H., Zehentner, B.K., Eidenschink, L., Ghirardelli, K.M., Biggerstaff, J.S. & Loken, M.R. (2011) Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytometry Part B Clinical Cytometry, 80, 150-157.
6. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
7. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstöcker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
8. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds). (2001) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 3rd edn. International Agency For Research on Cancer (IARC) Press, Lyon, France.
9. Kern, W., Haferlach, C., Schnittger, S. & Haferlach, T. (2010) Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome. Cancer, 116, 4549-4563.
10. van de Loosdrecht, A.A., Westers, T.M., Westra, A.H., Dräger, A.M., van der Velden, V.H. & Ossenkoppele, G.J. (2008) Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood, 111, 1067-1077.
11. van de Loosdrecht, A.A., Alhan, C., Béné, M.C., Della Porta, M.G., Dräger, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., te Marvelde, J.G., Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W., Richards, S.J., Schuurhuis, G.J., Subirá, D., Valent, P., van der Velden, V.H., Vyas, P., Westra, A.H., de Witte, T.M., Wells, D.A., Loken, M.R. & Westers, T.M. (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica, 94, 1124-1134.
12. van de Loosdrecht, A.A., Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Dräger, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellström-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., te Marvelde, J.G., Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F., Psarra, K., Richards, S.J., Subirá, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., van der Velden, V.H., Wells, D.A., de Witte, T.M., Zettl, F., Béné, M.C. & Westers, T.M. (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia & Lymphoma, 54, 472-475.
13. Malcovati, L., Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. & Cazzola, M. (2005a) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23, 7594-7603.
14. Malcovati, L., Della Porta, M.G., Lunghi, M., Pascutto, C., Vanelli, L., Travaglino, E., Maffioli, M., Bernasconi, P., Lazzarino, M., Invernizzi, R. & Cazzola, M. (2005b) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia, 19, 776-783.
15. Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M.G., Pascutto, G., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., Strupp, C., Lazzarino, M., Aul, C. & Cazzola, M. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology, 25, 3503-3510.
16. Malcovati, L., Della Porta, M.G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., Germing, U. & Cazzola, M. (2011) Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica, 96, 1433-1440.
17. Matarraz, S., López, A., Barrena, S., Fernandez, C., Jensen, E., Flores-Montero, J., Rasillo, A., Sayagues, J.M., Bárcena, P., Hernandez-Rivas, J.M., Salvador, C., Fernandez-Mosteirín, N., Giralt, M., Perdiguer, L., Laranjeira, P., Paiva, A. & Orfao, A. (2010) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry Part B Clinical Cytometry, 78, 154-168.
18. Mitelman, F. (ed.) (1995) ISCN: An International System for Human Cytogenetic Nomenclature 1995. Karger press, Basel, Switzerland.
19. Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A., Aul, C., Lübbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Kantarjian, H., Germing, U., Haase, D. & Estey, E. (2011) Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. Journal of Clinical Oncology, 29, 1963-1970.
20. Scott, B.L., Wells, D.A., Loken, M.R., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2008) Validation of a FC scoring system as a prognostic indicator for post transplantation outcome in patients with myelodysplastic syndrome. Blood, 112, 2861-2866.
21. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A. & Stein, H. (eds). (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency For Research on Cancer (IARC) Press, Lyon, France.
22. Terwijn, M., Feller, N., van Rhenen, A., Kelder, A., Westra, G., Zweegman, S. & Schuurhuis, G.J. (2009) Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45, 1692-1699.
23. Valent, P., Horny, H.P., Bennett, J.M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H.J., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, K., Pfeilstöcker, M., Rüter, B., Sperr, W.R., Stauder, R. & Wells, D.A. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Research, 31, 727-736.
24. Wells, D.A., Benesch, M., Loken, M.R., Vallejo, C., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndromes correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394-403.
25. Westers, T.M., Alhan, C., Chamuleau, M.E., van der Vorst, M.J., Eeltink, C., Ossenkoppele, G.J. & van de Loosdrecht, A.A. (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood, 115, 1779-1784.
26. Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Della Porta, M.G., Dräger, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., te Marvelde, J.G., Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subirá, D., Tindell, V., Vallespi, T., Valent, P., van der Velden, V.H. & de Witte, T.M., Wells, D.A., Zettl, F., Béné, M.C., Béné, M.C. & van de Loosdrecht, A.A. (2012) Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 26, 1730-1741.